Objective: The primary objective of this study was to verify whether breast cancer patients aged ,35 at diagnosis have poorer prognoses than those aged 35 -39, in other words, to identify the prognostic value of age in younger premenopausal patients under 40 years old. The secondary objective was to assess prognostic factors specific for younger premenopausal patients. Methods: We identified 242 consecutive patients who were diagnosed with stage I -III breast cancer before the age of 40 and underwent surgery between 1990 and 2004. We compared disease-free survival and overall survival in patients aged ,35 years and those aged 35 -39 years, and evaluated clinicopathological factors associated with disease-free survival or overall survival in each age group and in all patients under the age of 40. Results: Ninety-nine (41%) patients were younger than 35 years and 143 (59%) were between 35 and 39 years. No significant difference in disease-free survival or overall survival was found between the two groups. In our cohort of patients under the age of 40, the independent factors associated with poor disease-free survival and overall survival included positive axillary lymph nodes and triple-negative status, but not age at diagnosis. Adverse prognostic factors also did not differ considerably between the two age groups. Conclusions: Age at diagnosis was not an independent prognostic factor in our study. Our findings suggest that other clinicopathological features rather than age should be used to determine individualized treatment courses for breast cancer patients younger than 40 years.
INTRODUCTION
Many studies have reported that younger women with primary breast cancer have poorer prognoses than older women. The St Gallen international expert consensus reports from 1998 to 2007 concluded the age of ,35 years was a high-risk factor for relapse in node-negative breast cancer patients and recommended adjuvant chemotherapy for most young women with breast cancer (1 -5) . However, the decision regarding chemotherapy in young patients must be made after taking into consideration not only the risk of relapse but also the age-specific problems caused by chemotherapy such as infertility, bone loss and changes in sexual function and appearance.
The cutoff value for classifying a patient as 'young' varies among studies and it is unclear whether the age of ,35 years at diagnosis was an appropriate threshold to identify patients with primary breast cancer at high risk of relapse. It also remains to be determined whether Japanese patients aged ,35 years at diagnosis have poorer prognoses since there have been few reports focusing on young Japanese women with breast cancer.
Prognostic factors in younger patients with primary breast cancer have been recently identified, but are not yet well understood. A recent study showed that gene expression profile was a powerful predictor of disease outcome in young patients with breast cancer, but age was not an independent prognostic factor (6) .
Gene expression profiling has identified intrinsic breast cancer subtypes that predict distinct clinical outcomes (7, 8) .
In particular, triple-negative breast cancer, defined by the lack of expression of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2), is known to be a subtype associated with poor clinical outcome. A high prevalence of triple-negative breast cancer has been reported to contribute to the poor prognosis of young African American women with breast cancer (9) .
The primary objective of this study was to verify whether breast cancer patients aged ,35 at diagnosis have poorer prognoses than those aged 35 -39 , in other words, to identify the prognostic value of age in younger premenopausal patients under 40 years old. The secondary objective was to assess the prognostic factors specific for younger premenopausal patients.
PATIENTS AND METHODS

PATIENTS AND TREATMENT
From the database of the National Cancer Center Hospital, Tokyo, Japan, we identified consecutive patients who were diagnosed with breast cancer before the age of 40 years and underwent surgery between January 1990 and December 2004. Only patients with stage I -III disease who underwent definitive surgery were included. Patients who had undergone preoperative adjuvant therapy or had excisional biopsy in a local clinic were also excluded because it is difficult to determine pathological factors influencing prognoses.
The complete medical records of patients enrolled in the study were reviewed. Information derived from the database and medical records included clinical and histological variables such as age; family history; pT ( primary tumor) and pN (regional lymph node) status; histological type; histological grade; peritumoral vessel invasion (PVI) [including lymphatic vessel invasion (LVI) and blood vessel invasion (BVI)]; ER, PgR and HER2; tumor subtype stratified by hormone receptor (HR) and HER2 status; operative procedure; radiation therapy; adjuvant systemic therapy (chemotherapy and endocrine therapy).
Familial breast cancer (that does not fit hereditary breast cancer definition) was defined as breast cancer with a family history of one or more first-or second-degree relatives with breast cancer prior to or at the time of the patient's initial diagnosis (10, 11) . In all cases, pT and pN status were assessed according to the UICC TNM classification (6th edition) (12) . Histological grade was evaluated according to Elston and Ellis (13) . ER and PgR expression were determined by enzyme immunoassay or immunohistochemistry (IHC) (threshold for positivity: staining in more than 10% of tumor cells) (14) . The definition of HER2 positive was a score 3þ by IHC (uniform, intense membrane staining in more than 10% of invasive cancer cells) and/or a 2.0 or higher of HER2/CEP17 (centromere probe chromosome 17) ratio by fluorescence in situ hybridization (15) . On the basis of the expression profile of HR and HER2, all tumors were categorized into one of the four subtypes: HRþHER22, HRþHER2þ, HR2HER2þ, HR2HER22 (triplenegative). HR-positive status (HRþ) was defined as ER and/ or PgR positivity, and HR-negative status (HR2) was defined as ER and PgR negativity. PVI was determined by the presence of tumor emboli within peritumoral endotheliallined spaces and was assessed on hematoxylin and eosinstained slides by making a distinction between lymphatic and blood vessels. LVI was graded as absent, focal to moderate (one to five foci of tumor thrombi in all the tumor specimens examined) or extensive (more than five foci of tumor thrombi in all the tumor specimens examined) (16) . BVI was classified as either absent or present.
All patients received clinically necessary local treatment (breast-conserving surgery or mastectomy) in addition to sentinel node biopsy or complete axillary dissection. Postoperative breast irradiation was indicated for all patients who underwent breast-conserving surgery. After 1999, patients with pT3 presentation who had undergone mastectomy received postoperative radiation to the chest wall. Patients with four or more metastatic axillary lymph nodes received postoperative radiation to the axillary and supraclavicular regions. Adjuvant chemotherapy was followed by radiotherapy for all indicated patients. The adjuvant chemotherapy regimen widely used prior to 1993 comprised doxorubicin, cyclophosphamide (AC), methotrexate and 5-fluorouracil. After 1993, patients generally received four cycles of intravenous doxorubicin and AC. After 1999, highrisk patients received AC followed by taxane (docetaxel or paclitaxel). For women with endocrine-responsive disease aged ,40 years, adjuvant endocrine therapy was indicated, such as tamoxifen for 2 -5 years or the combination of tamoxifen for 5 years plus gonadotropin-releasing hormone analogues for at least 2 years. Patients who received adjuvant chemotherapy for endocrine-responsive disease were treated with tamoxifen immediately after the completion of chemotherapy.
Patients were followed up every 3 -6 months during the first 5 years and every 6 -12 months from 5 to 10 years. In addition to physical examination, annual mammography with or without breast ultrasound was performed for 10 years. Blood tests including two tumor markers (carcinoembryonic antigen and cancer antigen 15-3), chest X-ray, abdominal ultrasonography and bone scintigraphy were performed when the patients complained of any symptoms and/ or tumor recurrence was suspected.
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STATISTICAL METHODS
The x 2 test (Pearson statistic) was used to determine the differences in clinical and pathological factors between two groups of patients. A P value of ,0.01 was considered statistically significant.
The follow-up duration was calculated as the length of time between the date of diagnosis and the date of death or last contact. Disease-free survival (DFS) was defined as the time from surgical resection to the first of any of the following events: locoregional relapse, distant relapse, second primary breast cancer, any second (non-breast) malignancy or death from any cause. Locoregional relapse was defined as the reappearance of cancer in the ipsilateral breast, chest wall or regional lymph nodes. We classified distant relapse into two categories depending on metastatic sites: nonvisceral (soft-tissue and/or bone) or visceral (including lung, liver, brain and other organs). Overall survival (OS) was defined as the time from surgical resection to death due to any cause, regardless of recurrence. DFS and OS curves were drawn by the Kaplan -Meier method and were compared among patient subsets using the log-rank test.
In univariate analyses, the following prognostic factors were evaluated for their potential associations with DFS and OS: age at the time of diagnosis, familial breast cancer, pT, pN, histological type, histological grade, LVI, BVI, tumor subtype stratified by HR and HER2 status, operative procedure, administration of radiation therapy and adjuvant systemic therapy. ER, PgR and HER2 were excluded from the prognostic analyses for DFS and OS because these factors are closely related to tumor subtype. Multivariate analysis of potential prognostic factors was performed to generate a Cox proportional hazards model. Multivariate models were created using age at diagnosis and other variables that showed significant association (P , 0.01) with DFS or OS on univariate analysis. All tests were two-tailed, with P , 0.01 being taken as an indicator of statistical significance. The statistical software SPSS version 12.0 (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses.
RESULTS
PATIENT CHARACTERISTICS
Out of a total of 3944 patients who underwent surgery at the National Cancer Center Hospital, Tokyo, Japan, between January 1990 and December 2004, 242 patients were eligible for this study. Of which 99 (41.0%) were aged ,35 years at diagnosis, and 143 (59.0%) were aged between 35 and 39 years ( Table 1 ). The median age at diagnosis was 36 years (range 22 -39 years). The distribution of various clinicopathological factors did not differ significantly between the two age groups. PgR positivity was observed in a higher percentage of patients aged 35 -39 years than in those aged ,35 years, but the proportion of patients falling into each of these four tumor subtypes did not differ significantly between the two groups. Sixty-nine percent of the 242 patients were classified as HRþHER22, 10.3% were HRþHER2þ, 5.8% were HR2HER2þ and 14.9% were HR2HER22 (triple-negative).
During (Fig. 1) . We did not also find a significant difference in frequency of occurrence of various DFS events between the two age groups (Table 1) .
UNIVARIATE ANALYSES
For breast cancer patients under 40 years old, univariate analyses showed that significant adverse factors associated with both DFS and OS included higher T stage (pT3 -4), positive lymph nodes (pN1 -3), grade 3, extensive LVI, BVI, triplenegative status and adjuvant chemotherapy (Tables 2 and 3) . With regard to adjuvant chemotherapy, patients who were treated with chemotherapy had significantly worse DFS and OS. No significant difference in survival was observed between the familial breast cancer group and the nonfamilial group.
MULTIVARIATE ANALYSES
For all patients under the age of 40, multivariate analyses identified positive axillary lymph nodes ( pN1 -pN3) and triple-negative status as independent factors associated with poor DFS and OS (Tables 2 and 3 , and Fig. 2) . Age, represented as either a categorical or a continuous variable, was not an independent prognostic factor in multivariate analyses. The independent factors negatively influencing DFS included pN1 (hazard ratio 3.69, 95% CI 1.61 -8.47), pN2 -pN3 (hazard ratio 6.55, 95% CI 2.72 -15.75) and triplenegative status (hazard ratio 2.45, 95% CI 1.37 -4.36). The independent adverse factors affecting OS included pN1 (hazard ratio 6.00, 95% CI 1.77 -20.35), pN2 -pN3 (hazard ratio 7.95, 95% CI 2.31 -27.37), the presence of BVI (hazard ratio 2.88, 95% CI 1.35 -6.13) and triple-negative status (hazard ratio 4.25, 95% CI 2.08 -8.72).
For patients aged ,35, multivariate analyses indicated that positive axillary lymph nodes ( pN1 -pN3) and triplenegative status were the independent factors associated with poor DFS and OS (Table 4) . For those aged 35 -39, triple-negative status was the only independent adverse prognostic factor identified. Axillary lymph node status was not found to be an independent factor, probably due to the
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DISCUSSION
Although being 'young' has been reported to be a predictor of poor prognosis independent of other known factors (17 -21) , the definition of 'young' has varied across studies. The age of 35 years has been used as a cutoff age based on consensus in the international guidelines for treatment of primary breast cancer (1 -5). However, the St Gallen international expert consensus panel discontinued the use of the threshold of 35 years of age as a risk category in 2009 (22) . The primary objective of this study was to verify whether breast cancer patients aged ,35 at diagnosis have poorer prognoses than those aged 35 -39 or to identify the prognostic value of age in younger premenopausal patients under 40 years old. Our results did not indicate any significant differences between patients aged ,35 years and those aged 35 -39 years in either DFS or OS, and age at diagnosis was not an independent factor associated with DFS or OS in our cohort of breast cancer patients younger than 40 years. We believe that these observations are reliable because the distribution of various clinical and pathological factors did not differ significantly between the two age groups.
A population-based study in Switzerland found no effect of young age on survival when accounting for breast tumor characteristics and treatment (23) . A study by van de Vijver et al. (6) also demonstrated that, whereas gene-expression profile was a powerful predictor of disease outcome in younger women with breast cancer, age was not an independent prognostic factor. Younger premenopausal women have been reported to more frequently present with breast cancer marked by poor prognostic features such as higher T stage, positive lymph nodes, endocrine non-responsiveness, high grade, extensive PVI and high proliferating fraction than older premenopausal women (24 -29) . Kollias et al. (25) concluded that age itself had no influence on the prognosis of individuals because the association of poor prognosis with young age at diagnosis could be explained by a higher proportion of aggressive tumors.
Our present study of breast cancer patients under the age of 40 supports these observations and we consider that the age of ,35 years at diagnosis is an unreasonable threshold to identify patients with primary breast cancer at high risk of relapse. 
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In contrast to our findings, de la Rochefordiere et al. (19) reported that, in a series of 1703 patients from a single institution, the relationship between recurrence hazard and age was best fitted by a log-linear function that indicated a 4% decrease in recurrence and a 2% decrease in death for every year of age in premenopausal women. Han and Kang also recently reported that in patients younger than 35 years, the risk of death rose by 5% for every year of decrease in age, whereas death risk did not vary significantly with age in patients aged 35 years or older (30) .
What is more, our unpublished data confirms that breast cancer patients aged ,40 years have poorer DFS than those aged 41 -49 years (5-year DFS: 79 vs. 86%, P ¼ 0.04), while no significant difference was found in OS (5-year OS: 86 vs. 90%, P ¼ 0.2). However, there were a much greater number of patients aged 41 -49 years compared with those aged ,40 years, and the difference in sample number between the two groups was beyond the allowed limit. Therefore, we limited ourselves only to calculating DFS and OS for patients between 40 and 49 years of age. Anders et al. (31) documented similar findings that survival rate in patients who were diagnosed before the age of 40 years was worse when compared with that in older women.
These results indicate that age does have some impact on long-term outcome of patients. Our report and unpublished data suggest that other clinicopathological features rather than age at diagnosis should be used to determine individualized treatment courses for breast cancer patients under 40 years old, but not across all age groups. Further analyses are needed in order to assess the prognostic value of age at diagnosis in women with primary breast cancer across all age groups. However, this can still be a significant finding given that women are now commonly bearing children at older ages in Japan.
Our secondary objective in this study was to assess prognostic factors specific for younger premenopausal women with primary breast cancer. We found that the most important factors associated with poor DFS and OS in patients under the age of 40 were positive axillary lymph nodes (pN1 -pN3) and triple-negative status. Triple-negative status was also an independent factor associated with worse DFS and OS in both age groups.
Previous studies have identified axillary lymph node status, HR and HER2 status, tumor size, histological grade, operative procedure, radiation therapy, adjuvant systemic therapy, family history of ovarian cancer and age ,35 or 40 
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Young Japanese women with breast cancer Figure 2 . Kaplan -Meier curves of DFS and OS compared between triple-negative breast cancer patients (n ¼ 36) and breast cancer patients whose tumors fall into one of the other three subtypes (non-triple-negative; n ¼ 206). years as independent prognostic factors in younger premenopausal patients (17,19 -21,23,24,27,28) . Axillary lymph node status in particular has been highlighted as a powerful independent prognostic parameter in women with primary breast cancer across all age groups. However, in the present study, axillary lymph node status was not an independent prognostic factor in patients aged 35 -39 years. This discrepancy with previous studies is likely the result of the subtraction effects of LVI and BVI, which significantly correlate with positive axillary lymph nodes. We also observed that, in univariate analyses, patients who were treated with chemotherapy had significantly worse DFS and OS. This finding reflects the significantly higher proportion of positive axillary lymph nodes in those patients. Taken together, these results support axillary lymph node status as an important prognostic factor.
The triple-negative subtype or the basal-like subtype (defined immunohistochemically as ER negative, HER2 negative and cytokeratin 5/6 and/or HER1 positive) (32) is associated with aggressive histology and poor clinical outcome. In our study, triple-negative status was confirmed as a prognostic factor for poorer long-term outcome. The triple-negative subtype accounts for 15% of the four tumor subtypes in the general population and for a higher percentage of breast cancer arising in African-American women (33, 34) which is a contributing factor to their poorer prognosis (9) . According to surveillance data from the Registration Committee of the Japanese Breast Cancer Society, the triple negative subtype accounts for 15.5% of breast cancers, with no difference in mean age at diagnosis among the four tumor subtypes (35) . In our study of breast cancer patients under age 40, the proportion of patients falling into each of these four tumor subtypes was approximately the same as that in a representative population of Japanese women with breast cancer, and did not differ significantly between patients aged ,35 and those aged 35 -39 years. Further studies are needed to clarify the associations between the factors involved in triple-negative status, younger onset and poorer prognosis in patients with breast cancer.
In conclusion, our results did not indicate any significant differences between patients aged ,35 years and those aged 35 -39 years in either DFS or OS. In our cohort of breast cancer patients under the age of 40, the independent factors associated with poor DFS and OS included positive axillary lymph nodes (pN1 -pN3) and triple-negative status, but not age at diagnosis. Adverse prognostic factors also did not differ considerably between the two age groups. Our findings suggest that other clinicopathological features rather than age should be used to determine individualized treatment courses for breast cancer patients younger than 40 years.
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